Kenneth was appointed to finance leadership positions at Pharming Group N.V. in September 2025.
1 report, 1 independent
Updated Sep 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Kenneth was appointed to finance leadership positions at Pharming Group N.V. in September 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Kenneth
Nothing else this week.
-
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
Coverage
Newest first; wire copies grouped- GlobeNewswirePharming Group appoints Kenneth Lynard as Chief Financial Officer Leiden, the Netherlands, September 2, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today a